Enhancing "Liquid Biopsy" Accuracy with Fragmentomics and the Detection of Early-Stage Multi-Cancer Signals within the Biomarkers Sector for Early 2026
The "Holy Grail" of cancer screening—a single blood test to detect dozens of cancers—is becoming a reality in early 2026 through "Fragmentomics." This advanced branch of liquid biopsy doesn't just look for "mutations"; it analyzes the "fragmentation patterns" of cell-free DNA (cfDNA) in the blood. Because different tissues pack their DNA differently, the "shredding" pattern acts as...
0 Comments 0 Shares 235 Views 0 Reviews